Furthermore, aberrant alternative splicing of the NF-κB inhibitor CYLD may lead to chronic activaiton of NF-κB in some cases of chronic lymphocytic leukemia [62]. Here, NFKB1 is linked to B-cell chronic lymphocytic leukemia.